fluticasone furoate and vilanterol inhalation powder (Breo Ellipta)

  • Medical Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical and Pharmacy Editor: Jay W. Marks, MD
    Jay W. Marks, MD

    Jay W. Marks, MD

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

GENERIC NAME: fluticasone furoate and vilanterol inhalation powder

BRAND NAMES: Breo Ellipta

DRUG CLASS AND MECHANISM: Breo Ellipta for oral inhalation is a combination of fluticasone and vilanterol and is used for treating chronic obstructive pulmonary disease (COPD). Fluticasone is a man-made steroid of the glucocorticoid family which is related to the naturally-occurring steroid hormone, cortisol or hydrocortisone, produced by the adrenal glands. Glucocorticoid steroids have potent anti- inflammatory actions. When used as an inhaler, fluticasone travels to the airways in the lung. In COPD patients, the suppression of inflammation within the airways reduces the inflammatory-stimulated spasm of the smooth muscle cells surrounding the airways that narrows the airways and makes getting air into and out of the lungs more difficult. When used in lower doses, very little fluticasone is absorbed into the body. When higher doses are used, fluticasone is absorbed and may cause side effects elsewhere in the body.

Vilanterol is a bronchodilator of the beta-2 agonist type. Beta-2 agonists are medications that stimulate beta-2 receptors on the smooth muscle cells that surround the airways, causing these muscle cells to relax and thereby opening the airways. It is similar to salmeterol (Serevent). Breo Ellipta opens the airways and increases air supply to the lungs of COPD patients. The FDA approved Breo Ellipta in May 2013.

PRESCRIBED FOR: Breo Ellipta is used for long-term treatment of COPD (emphysema or chronic bronchitis). Breo Ellipta is not used for acute episodes of bronchospasm or treatment of asthma.

Medically Reviewed by a Doctor on 5/26/2015

Quick GuideCOPD Lung Symptoms, Diagnosis, Treatment

COPD Lung Symptoms, Diagnosis, Treatment
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Allergy and Asthma Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors